NCT04474470 - A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 3, 2020

Primary Completion Date

May 8, 2024

Study Completion Date

May 8, 2024

Conditions

Solid Tumor, AdultSquamous Cell Carcinoma of Head and NeckColorectal AdenocarcinomaMetastatic Solid TumorRecurrent Solid TumorHead and Neck Cancer

Interventions

DRUG

NT219

Dose escalation of NT219 as a single agent in adult subjects with recurrent and/or metastatic solid tumors

DRUG

NT219 and ERBITUX® - Dose Escalation

Dose escalation of NT219 in combination with standard dose ERBITUX® in adult subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck and colorectal adenocarcinoma

DRUG

NT219 and ERBITUX® - Expansion

Expansion cohort of NT219 at its RP2D in combination with standard dose ERBITUX® in adult patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Trial Locations (10)

20007

MedStar Georgetown University Hospital, Washington D.C.

60637

The University of Chicago and Biological Sciences, Chicago

70121

Ochsner Clinic Foundation, New Orleans

73117

Stephenson Cancer Center, Oklahoma City

90025

The Angeles Clinic and Research Institute, Los Angeles

92024

California Cancer Associates for Research and Excellence, Encinitas

92037

UCSD Moores Cancer Center, San Diego

Unknown

Hadassah University Medical Center, Jerusalem

Rabin Medical Center, Petah Tikva

Sourasky Medical Center, Tel Aviv

All Listed Sponsors

lead

TyrNovo Ltd.

INDUSTRY